Lumosa Therapeutics Co (ROCO:6535) Additional Paid-In Capital : NT$2,219.20 Mil(As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Lumosa Therapeutics Co Additional Paid-In Capital?

Lumosa Therapeutics Co's quarterly additional paid-in capital increased from Sep. 2024 (NT$1,365.37 Mil) to Dec. 2024 (NT$2,223.22 Mil) but then stayed the same from Dec. 2024 (NT$2,223.22 Mil) to Mar. 2025 (NT$2,219.20 Mil).

Lumosa Therapeutics Co's annual additional paid-in capital increased from Dec. 2022 (NT$1,268.44 Mil) to Dec. 2023 (NT$1,362.55 Mil) and increased from Dec. 2023 (NT$1,362.55 Mil) to Dec. 2024 (NT$2,223.22 Mil).

Lumosa Therapeutics Co Additional Paid-In Capital Historical Data

The historical data trend for Lumosa Therapeutics Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumosa Therapeutics Co Additional Paid-In Capital Chart

Lumosa Therapeutics Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

963.36

1,271.37

1,268.44

1,362.55

2,223.22

Lumosa Therapeutics Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,362.05	1,360.49	1,365.37	2,223.22	2,219.20

Lumosa Therapeutics Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Lumosa Therapeutics Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Lumosa Therapeutics Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumosa Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503

Website

https://www.lumosa.com.tw

Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.

Lumosa Therapeutics Co Headlines

No Headlines